Skip to Content
  • MyChart

    Log in to our secure, personalized website to manage your care (formerly myMDAnderson).

  • Request an Appointment

    If you are ready to make an appointment, select a button on the right. If you have questions about UT MD Anderson’s appointment process, our information page may be the best place to start.

    Appointment Information
    New Patients Current Patients Referring Physicians
  • Every Breakthrough
    Begins With You

    Gifts to UT MD Anderson’s historic philanthropic campaign help accelerate discovery, transform lives and bring hope to more patients than ever before.

    Learn more about Only Possible Here
    Donate Today only-possible-here-logo
The University of Texas MD Anderson Cancer Center
  • Clinical Trials
  • Locations
  • Careers
  • Contact Us
  • Our Doctors
    • Español
    • عربى
    • 中文
    • Türkçe
Clear
close
      MyChart
      Donate Today
      • Clinical Trials
      • Locations
      • Careers
      • Contact Us
        • Español
        • عربى
        • 中文
        • Türkçe
      • Request an Appointment
      • New Patients
      • Current Patients
      • Referring Physicians
      • Patients & Family
          • Becoming Our Patient Home
          • Why UT MD Anderson
          • Planning for Care
          • Getting to UT MD Anderson
          • While You're Here
          • International Center
          • Services and Amenities
          • Insurance & Billing
          • Second Opinion Appointments
          • Diagnosis & Treatment Home
          • Cancer Types
          • A New Diagnosis
          • Treatment Options
          • Care Centers & Clinics
          • Emotional & Physical Effects
          • Patient Support
          • Clinical Trials
          • Supporting a Loved One Home
          • Caregiver Roles & Challenges
          • Children and Teens
          • Taking Care of Yourself
          • Helping a UT MD Anderson Patient
          • Dealing with Loss
          • Life After Cancer Home
          • Follow-up Care After Cancer Treatment
          • Long-Term Effects of Cancer
          • Social & Emotional Impacts of Cancer
          • Legal & Financial Impacts of Cancer
          • Survivorship Week
        • Request an Appointment Current Patients

          Find information and resources for current and returning patients.

          Clinical Trials

          Learn about clinical trials at UT MD Anderson and search our database for open studies.

      • Prevention & Screening
          • Manage Your Risk Home
          • Tobacco Control
          • Diet
          • Body Weight
          • Physical Activity
          • Skin Safety
          • HPV
          • Hepatitis
          • Alcohol
          • Family History Home
          • Genetic Testing
          • Hereditary Cancer Syndromes
          • Genetic Counseling and Testing FAQs
          • Cancer Screenings Home
          • Mammograms & Breast Cancer Screening
          • Cervical Cancer Screening
          • Colorectal Cancer Screening
          • Endometrial Cancer Screening
          • Liver Cancer Screening
          • Lung Cancer Screening
          • Mobile Mammography
          • Ovarian Cancer Screening
          • Prostate Cancer Screening
          • Skin Cancer Screening
          • Women's Cancer Screening
          • Men's Cancer Screening
        • Cancer Prevention Center 

          The Lyda Hill Cancer Prevention Center provides cancer risk assessment, screening and diagnostic services.

      • Donors & Volunteers
          • Donate Home
          • Raise Money
          • Honor Loved Ones
          • Create Your Legacy
          • Endowments
          • Caring Fund
          • Matching Gifts
          • Foundation and Corporation Relations
          • Volunteer Home
          • Why Volunteer
          • On-Site Volunteers
          • Volunteer Endowment
          • Patient Experience
          • Teen Volunteer Leadership Program
          • Children's Cancer Hospital Councils
          • Other Ways to Help Home
          • Give Blood
          • Shop UT MD Anderson
          • Children's Art Project
          • Donate Goods or Services
          • Attend Events
          • Cord Blood Bank
          • Corporate Alliances Home
          • Current Alliances
        • Join the Campaign to End Cancer 

          Help us celebrate and fuel the groundbreaking innovations and transformative advancements that define UT MD Anderson.

      • For Physicians
          • Refer a Patient Home
          • Health Care Provider Resource Center
          • Referring Provider Team
          • Insurance Information
          • International Referrals
          • myMDAnderson for Physicians
          • Second Opinion Pathology
          • Clinical Trials Home
          • Clinical Tools & Resources Home
          • Clinical Calculators
          • Clinical Practice Algorithms
        • myMDAnderson for Physicians 

          Our personalized portal helps you refer your patients and communicate with their UT MD Anderson care team.

      • Research
          • Departments, Labs and Institutes Home
          • Departments and Divisions
          • Labs
          • Research Centers and Programs
          • Institutes
          • Specialized Programs of Research Excellence (SPORE) Grants
          • Research Areas Home
          • Basic Science
          • Translational Research
          • Clinical Research
          • Prevention & Personalized Risk Assessment
          • Research Resources Home
          • Excellence in Science
          • Core Facilities and Services
          • Conferences & Seminars
          • Why Research at UT MD Anderson
          • STRIDE
          • NCI-Designated Cancer Center
          • Data Resources
        • Clinical Trials 

          As part of our mission to eliminate cancer, UT MD Anderson researchers conduct hundreds of clinical trials to test new treatments for both common and rare cancers.

      • Education & Training
          • Degree-Granting Schools Home
          • School of Health Professions
          • MD Anderson UTHealth Houston Graduate School
          • Research Training Home
          • Early Career Pathway Programs
          • Predoctoral Training
          • Postdoctoral Training
          • Mentored Faculty Programs
          • Career Development
          • Clinical Training Home
          • Graduate Medical Education
          • Clinical Education for Non-Physicians
          • Nursing Education & Training
          • Continuing Education & Review Courses
          • Simulation Center
          • Continuing Education & Professional Development Home
          • Continuing Professional Education/Conferences
          • Administrative Internships & Fellowships
          • Cancer Survivorship Professional Education
          • Leadership Institute
          • Patient Home Visits
          • Education Resources Home
          • Alumni Relations
          • Education Design Services
          • Awards & Recognitions
          • Academic Mentoring Council
          • Why UT MD Anderson & Houston
          • Outreach Programs Home
          • Project ECHO
          • Observer Programs
          • Comparative Effectiveness Training (CERTaIN)
          • Faculty Speakers Bureau
        • Apply to SHP

          Choose from 12 allied health programs at School of Health Professions.

          Research Trainees

          View open postdoctoral and other research trainee positions.

          GME Fellowships

          Learn about our graduate medical education residency and fellowship opportunities.

      Jae-Il Park Image

      Jae-Il Park, Ph.D.

      Department of Experimental Radiation Oncology, Division of Radiation Oncology

      Present Title & Affiliation

      Primary Appointment

      Professor, Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX

      Dual/Joint/Adjunct Appointment

      Professor, The University of Texas MD Anderson Cancer Center, Houston, Texas

      Research Interests

      The overarching goal of our research program is to understand the mechanisms of tumorigenesis and tissue regeneration by employing genetically engineered mice and organoids. Our recent investigations have aimed to address two critical questions: Is cell plasticity a therapeutic vulnerability of cancer? Can manipulating cell plasticity promote tissue regeneration, or prevent tissue damage?

      Education & Training

      Degree-Granting Education

      2006The University of Texas MD Anderson Cancer Center, Houston, Texas, US, Ph.D. in Genes and Development (advisor: Pierre D. McCrea, PhD)
      2001Korea University, Seoul, M.S. in Molecular Biology (advisor: Sung-Gil Chi, PhD)
      1999Korea University, Seoul, BS in Biology

      Postgraduate Training

      2006-2010Postdoctoral Fellow, Stanford University School of Medicine, Stanford, California

      Experience & Service

      Faculty Academic Appointments

      Associate Professor, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2016 - 2022

      Assistant Professor, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2010 - 2016

      Extramural Institutional Committee Activities

      Committee Member, CCSG Program Income Advisory Committee, The University of Texas MD Anderson Cancer Center, 2023 - Present

      Faculty Senator, The Faculty Senate, The University of Texas MD Anderson Cancer Center, 2016 - 2018

      Committee member, Admission Committee - The University of Texas - Graduate School of Biomedical Sciences, The University of Texas MD Anderson Cancer Center, 2015 - 2018

      Committee member, Institutional Animal Care and Use Committee, The University of Texas MD Anderson Cancer Center, 2015 - 2021

      Committee member, Faculty Academic Review Committee, The University of Texas MD Anderson Cancer Center, 2015 - Present

      Editorial Activities

      Associate Editor, BMC Cancer, 2019 - Present

      Honors & Awards

      2024Plenary Award, IMKASID
      2015DOD CDMRP Career Development Award
      2014 - 2017CPRIT Scholar
      2011AACR - Career Development Award, PANCAN
      2011CCSG New Faculty Award, MD Anderson Cancer Center
      2011Rising STARS Award, University of Texas
      2008 - 2009Stanford Comprehensive Cancer Center Fellowship, Stanford School of Medicine
      2007Dean's Fellowship, Stanford School of Medicine
      2006Presidents' Scholar Award, UT M. D. Anderson Cancer Center and UT Health Science Center
      2006Grady Saunders Award, UT M. D. Anderson Cancer Center
      2005 - 2006Rosalie B. Hite Fellowship, UT M. D. Anderson Cancer Center
      2005Research Achievement Award, UT M. D. Anderson Cancer Center
      2005Travel Award, Graduate School of Biomedical Sciences, UT Health Science Center
      2005Travel Award, UT M. D. Anderson Cancer Center
      2004Research Achievement Award, UT M. D. Anderson Cancer Center
      1999Magna Cum Laude, Korea University
      1997Honors Scholarships, Korea University
      1992Freshman Special Scholarship, Korea University

      Professional Memberships

      American Gastroenterological Association

      2017 - Present

      International Society for Stem Cell Research

      2017 - Present

      Radiation Research Society

      2016 - Present

      American Society for Biochemistry and Molecular Biology

      2013 - Present

      American Association for Cancer Research

      2007 - Present

      Society for Developmental Biology

      2005 - 2006

      Korean Cancer Association

      2000 - 2002

      Selected Presentations & Talks

      Formal Peers

      1. 2023. Cell Plasticity and Cancer. Invited, US.
      2. 2023. Modeling, dissecting, and targeting mucinous colon adenocarcinoma. Invited, US.
      3. 2021. DREAMing Cancer and Regeneration. Invited. Seoul.
      4. 2019. Targeting DREAM Complex for Cancer Treatment and Prevention. Invited. Charlottesville, VA, US.
      5. 2018. Manipulating Wnt signaling in cancer and stem cells. Invited. Chicago, IL, US.
      6. 2018. Dissecting Wnt signaling in stem cells and cancer. Invited. Seoul.
      7. 2017. Manipulating Wnt signaling in cancer and stem cells. Invited. Houston, TX, US.
      8. 2017. Dissecting Wnt signaling in cancer and stem cells. Invited. Houston, TX, US.
      9. 2017. Dissecting Wnt signaling in regeneration and cancer. Invited. Charleston, SC, US.
      10. 2017. Dissecting Wnt signaling in regeneration and cancer. Invited. Houston, TX, US.
      11. 2015. Wnt Signaling Regulators in Stem Cells and Cancer. Invited. Hamilton, Ontario, CA.
      12. 2015. Wnt Signaling Regulators in Stem Cells and Cancer. Invited. Huntsville, TX, US.
      13. 2014. Wnt Signaling and Cell Plasticity in Cancer. Invited. Charlottesville, VA, US.
      14. 2013. Wnt and Telomerase in Pancreatic Cancer. Invited. LA, CA, US.
      15. 2013. Wnt Signaling-Induced Cell Plasticity in Breast Cancer Stem Cells. Invited. Dae-Jeon.
      16. 2013. Wnt and Cell Plasticity in Stem Cells and Cancer. Invited. Seoul.
      17. 2013. Wnt and Cell Plasticity in Stem Cells and Cancer. Invited. Seoul.
      18. 2012. Wnt signaling in development and cancer. Invited. Baltimore, US.
      19. 2010. Telomerase in Development and Cancer. Invited. Oklahoma City, US.
      20. 2010. Telomerase in self-renewal and proliferation. Invited. Frederick, MD, US.
      21. 2010. Telomerase in self-renewal and proliferation. Invited. Houston, TX, US.
      22. 2009. Non-canonical role of telomerase in cancer and stem cells. Invited. Dae-Jeon.
      23. 2008. Telomerase beyond telomere. Invited. San Francisco, CA, US.
      24. 2007. Telomerase modulates Wnt signaling in stem cells. Invited. Seoul.
      Read More
      Less

      Grant & Contract Support

      Date: 2024 - 2029
      Title:Mechanisms of Esophageal Squamous Cell Cancer Initiation
      Funding Source:NIH/NCI
      Role:Mentor
      ID:K99 CA286761
      Date: 2024 - 2028
      Title:CRACD-controlled cell plasticity and small cell lung cancer
      Funding Source:NIH/NCI
      Role:PI
      ID:R01 CA278967
      Date: 2023 - 2028
      Title:Esophageal Squamous Cell Cancer Initiation and Immune Landscape Remodeling
      Funding Source:NIH/NCI
      Role:PI
      ID:R01 CA278971
      Date: 2023 - 2025
      Title:Calcium metabolism and lung cancer preneoplasia
      Funding Source:NIH/NCI
      Role:PI
      ID:R03 CA279867
      Date: 2022 - 2024
      Title:Cell Lineage Plasticity in Lung Preneoplasia
      Funding Source:UT MD Anderson Cancer Center
      Role:PI
      Date: 2020 - 2025
      Title:PAF-Remodeled DREAM Complex in Cancer and Regeneration
      Funding Source:NIH/NCI
      Role:PI
      ID:2R01 CA193297
      Title:NeuralCODR Training Program
      Funding Source:NIH/NCI
      Role:CO-I
      ID:T32

      Selected Publications

      Peer-Reviewed Articles

      1. Jang J, Ko KP, Zhang J, Jun S, Park JI. Deciphering precursor cell dynamics in esophageal preneoplasia via genetic barcoding and single-cell transcriptomics. Proc Natl Acad Sci U S A. e-Pub 2025. PMID: 41337486.
      2. Park JI, Ko KP. Genetic Engineering of Esophageal Organoids: CRISPR-Based Knock-In for Cell Lineage Tracing. e-Pub 2025. PMID: 41071231.
      3. Kim B, Park J. Protocol for establishing genetically engineered murine lung organoids mimicking cell plasticity and regeneration. STAR Protoc 6(3), 2025. e-Pub 2025. PMID: 40543035.
      4. Chun S, Park E, Jang M, Park J, Jang Y. Sulfiredoxin stimulates luteinization in vitro by promoting progesterone production in rats, 2025. e-Pub 2025. PMID: 40891754.
      5. Dhar, SS, Ko, KP, Jang, J, Brown-Abel, C, Lin, T, Awasthi, S, Chen, K, Sillitoe, RV, Park, J, Lee, MG. KMT2D temporally activates neuronal transcriptional factor genes to mediate cerebellar granule cell differentiation. Science Advances 11(39), 2025. e-Pub 2025. PMID: 41004595.
      6. Kim, HK, Xing, J, Jung, Y, Park, J, Kim, HY, Kim, J, Abdi, S. Exacerbation of paclitaxel-induced neuropathic pain behaviors in breast tumor–bearing mice. Molecular pain 21, 2025. e-Pub 2025. PMID: 40913249.
      7. Kim B, Huang Y, Ko K, Zhang S, Zou G, Zhang J, Kim MJ, Little D, Ellis LV, Paschini M, Jun S, Park K, Chen J, Kim C, Park J. PCLAF-DREAM Drives Alveolar Cell Plasticity for Lung Regeneration. Nature Communications 15(1), 2024. e-Pub 2024. PMID: 39448571.
      8. Park JI. Peroxiredoxin 1-Toll-like receptor 4-p65 axis inhibits receptor activator of nuclear factor kappa-B ligand-mediated osteoclast differentiation. iScience, 2024. PMID: 39720522.
      9. Seo Y, Zhang S, Jang J, Ko K, Kim K, Huang Y, Kim D, Kim B, Zou G, Zhang J, Jun S, Chu W, Kirk NA, Hwang YE, Ban YH, Dhar SS, Chan JM, Lee MG, Rudin CM, Park K, Park J. Actin Dysregulation Induces Neuroendocrine Plasticity and Immune Evasion: A Vulnerability of Small Cell Lung Cancer. bioRxiv, 2024. PMID: 36824957.
      10. Feng X, Yang C, Huang Y, Su D, Wang C, Wilson LL, Yin L, Tang M, Li S, Chen Z, Zhu D, Wang S, Zhang S, Zhang J, Zhang H, Nie L, Huang M, Park JI, Hart T, Jiang D, Jiang K, Chen J. In vivo CRISPR screens identify Mga as an immunotherapy target in triple-negative breast cancer. Proc Natl Acad Sci U S A 121(39):e2406325121, 2024. e-Pub 2024. PMID: 39298484.
      11. Kim, B, Zhang, S, Huang, Y, Ko, KP, Jung, Y, Jang, J, Zou, G, Zhang, J, Jun, S, Kim, KB, Park, KS, Park, J. CRACD loss induces neuroendocrine cell plasticity of lung adenocarcinoma. Cell Reports 43(6), 2024. e-Pub 2024. PMID: 38796854.
      12. Ko K, Zhang S, Huang Y, Kim B, Zou G, Jun S, Zhang J, Zhao Y, Martin C, Dunbar KJ, Efe G, Rustgi AK, Nakagawa H, Zhang H, Liu Z, Park J. Tumor Niche Network-Defined Subtypes Predict Immunotherapy Response of Esophageal Squamous Cell Cancer. iScience 27(5), 2024. e-Pub 2024. PMID: 38741711.
      13. Zou, G, Huang, Y, Zhang, S, Ko, KP, Kim, B, Zhang, J, Venkatesan, V, Pizzi, M, Fan, Y, Jun, S, Niu, N, Wang, H, Song, S, Ajani, JA, Park, J. E-cadherin loss drives diffuse-type gastric tumorigenesis via EZH2-mediated reprogramming. J Exp Med 221(4), 2024. e-Pub 2024. PMID: 38411616.
      14. Ko KP, Huang Y, Zhang S, Zou G, Kim B, Zhang J, Jun S, Martin C, Dunbar KJ, Efe G, Rustgi AK, Nakagawa H, Park JI. Key Genetic Determinants Driving Esophageal Squamous Cell Carcinoma Initiation and Immune Evasion. Gastroenterology 165(3):613-628.e20, 2023. e-Pub 2023. PMID: 37257519.
      15. Zhang S, Lee SH, Nie L, Huang Y, Zou G, Jung YS, Jun S, Zhang J, Lien EM, Chen J, Park JI. Lysosomal TMEM9-LAMTOR4-controlled mTOR signaling integrity is required for mammary tumorigenesis. Cancer Communications 43(1):159-163, 2023. e-Pub 2023. PMID: 36336962.
      16. Kim KB, Kim DW, Kim Y, Tang J, Kirk N, Gan Y, Kim B, Fang B, Park JL, Zheng Y, Park KS. WNT5A-RHOA Signaling Is a Driver of Tumorigenesis and Represents a Therapeutically Actionable Vulnerability in Small Cell Lung Cancer. Cancer Research 82(22):4219-4233, 2022. e-Pub 2022. PMID: 36102736.
      17. Ko, KP, Zhang, J, Park, J. Establishing transgenic murine esophageal organoids. STAR Protocols 3(2), 2022. e-Pub 2022. PMID: 35496812.
      18. Kim KB, Kabra A, Kim DW, Xue Y, Huang Y, Hou PC, Zhou Y, Miranda LJ, Park JI, Shi X, Bender TP, Bush JH, Park KS. KIX domain determines a selective tumor-promoting role for EP300 and its vulnerability in small cell lung cancer. Science Advances 8(7), 2022. e-Pub 2022. PMID: 35171684.
      19. Zheng B, Ko KP, Fang X, Wang X, Zhang J, Jun S, Kim BJ, Luo W, Kim MJ, Jung YS, Cervantes CL, Park JI. A new murine esophageal organoid culture method and organoid-based model of esophageal squamous cell neoplasia. iScience 24(12):103440, 2021. e-Pub 2021. PMID: 34877497.
      20. Kim MJ, Cervantes C, Jung YS, Zhang X, Zhang J, Lee SH, Jun S, Litovchick L, Wang W, Chen J, Fang B, Park JI. PAF Remodels the DREAM Complex to Bypass Cell Quiescence and Promote Lung Tumorigenesis. Mol Cell 81(8):1698-1714.e6, 2021. e-Pub 2021. PMID: 33626321.
      21. Jung YS, Stratton SA, Lee SH, Kim MJ, Jun S, Zhang J, Zheng B, Cervantes CL, Cha JH, Barton MC, Park JI. TMEM9-v-ATPase Activates Wnt/β-Catenin Signaling via APC Lysosomal Degradation for Liver regeneration and Tumorigenesis. Hepatology 73(2):776-794, 2021. e-Pub 2021. PMID: 32380568.
      22. Kim HK, Bae J, Lee SH, Hwang SH, Kim MS, Kim MJ, Jun S, Cervantes CL, Jung YS, Back S, Lee H, Lee SE, Dougherty PM, Lee SW, Park JI, Abdi S. Blockers of Wnt3a, Wnt10a, or β-Catenin Prevent Chemotherapy-Induced Neuropathic Pain In Vivo. Neurotherapeutics 18(1):601-614, 2021. e-Pub 2021. PMID: 33128175.
      23. Shen X, Wang R, Kim MJ, Hu Q, Hsu CC, Yao J, Klages-Mundt N, Tian Y, Lynn E, Brewer TF, Zhang Y, Arun B, Gan B, Andreeff M, Takeda S, Chen J, Park JI, Shi X, Chang CJ, Jung SY, Qin J, Li L. A Surge of DNA Damage Links Transcriptional Reprogramming and Hematopoietic Deficit in Fanconi Anemia. Mol Cell 80(6):1013-1024.e6, 2020. e-Pub 2020. PMID: 33338401.
      24. Jung YS, Jun S, Kim MJ, Lee SH, Suh HN, Lien EM, Jung HY, Lee S, Zhang J, Yang JI, Ji H, Wu JY, Wang W, Miller RK, Chen J, McCrea PD, Kopetz S, Park JI. TMEM9 promotes intestinal tumorigenesis through vacuolar-ATPase-activated Wnt/β-catenin signaling. Nature Cell Biology 20(12):1421-1433, 2018. e-Pub 2018. PMID: 30374053.
      25. Jung YS, Wang W, Jun S, Zhang J, Srivastava M, Kim MJ, Lien EM, Shang J, Chen J, McCrea PD, Zhang S, Park JI. Deregulation of CRAD-controlled cytoskeleton initiates mucinous colorectal cancer via β-catenin. Nature Cell Biology 20(11):1303-1314, 2018. e-Pub 2018. PMID: 30361697.
      26. Kim MJ, Xia B, Suh HN, Lee SH, Jun S, Lien EM, Zhang J, Chen K, Park JI. PAF-Myc-Controlled Cell Stemness Is Required for Intestinal Regeneration and Tumorigenesis. Developmental Cell 44(5):582-596.e4, 2018. e-Pub 2018. PMID: 29533773.
      27. Suh HN, Kim MJ, Jung YS, Lien EM, Jun S, Park JI. Quiescence Exit of Tert+ Stem Cells by Wnt/β-Catenin Is Indispensable for Intestinal Regeneration. Cell Reports 21(9):2571-2584, 2017. e-Pub 2017. PMID: 29186692.
      28. Suh HN, Jun S, Oh AY, Srivastava M, Lee S, Taniguchi CM, Zhang S, Lee WS, Chen J, Park BJ, Park JI. Identification of KIAA1199 as a Biomarker for Pancreatic Intraepithelial Neoplasia. Scientific Reports 6:38273, 2016. e-Pub 2016. PMID: 27922049.
      29. Jun S, Jung YS, Suh HN, Wang W, Kim MJ, Oh YS, Lien EM, Shen X, Matsumoto Y, McCrea PD, Li L, Chen J, Park JI. LIG4 mediates Wnt signaling-induced radioresistance. Nature Communications 7:10994, 2016. e-Pub 2016. PMID: 27009971.
      30. Wang X, Jung YS, Jun S, Lee S, Wang W, Schneider A, Sun Oh Y, Lin SH, Park BJ, Chen J, Keyomarsi K, Park JI. PAF-Wnt Signaling-Induced Cell Plasticity Is Required for Maintenance of Breast Cancer Cell Stemness. Nature Communications doi:10.1038/ncomms10633:10633, 2016. e-Pub 2016. PMID: 26843124.
      31. Jung YS, Jun S, Lee SH, Sharma A, Park JI. Wnt2 complements Wnt/β-catenin signaling in colorectal cancer. Oncotarget 6(35)(35):37257-68, 2015. e-Pub 2015. PMID: 26484565.
      32. Wang W, Li X, Lee M, Jun S, Aziz KE, Feng L, Tran MK, Li N, McCrea PD, Park JI, Chen J. FOXKs Promote Wnt/β-Catenin Signaling by Translocating DVL into the Nucleus. Developmental Cell 32(6):707-18, 2015. e-Pub 2015. PMID: 25805136.
      33. Lee M, Ji H, Furuta Y, Park JI, McCrea PD. P120-catenin regulates REST/CoREST, and modulates mouse embryonic stem cell differentiation. J Cell Sci 127(Pt 18):4037-51, 2014. e-Pub 2014. PMID: 25074806.
      34. Jun S, Lee SH, Kim HC, Ng C, Schneider AM, Ji H, Ying H, Wang H, DePinho RA, Park JI. PAF-Mediated MAPK Signaling Hyperactivation via LAMTOR3 Induces Pancreatic Tumorigenesis. Cell Reports 21:2571-2584, 2013. e-Pub 2013. PMID: 24209743.
      35. Jung HY, Jun S, Lee M, Kim HC, Wang X, Ji H, McCrea PD, Park JI. PAF and EZH2 Induce Wnt/β-Catenin Signaling Hyperactivation. Molecular Cell 52(2):193-205, 2013. e-Pub 2013. PMID: 24055345.
      36. Wang X, Singh S, Jung HY, Yang G, Jun S, Sastry KJ, Park JI. HIV-1 Vpr Inhibits Telomerase Activity Via EDD-DDB1-VPRB3 E3 Ligase Complex. J Biol Chem 288(22):15474-80, 2013. e-Pub 2013. PMID: 23612978.
      37. Jung HY, Wang X, Jun S, Park JI. Dyrk2-Associated EDD-DDB1-VprBP E3 Ligase Inhibits Telomerase by TERT Degradation. J Biol Chem 288(10):7252-62, 2013. e-Pub 2013. PMID: 23362280.
      38. Wang W, Huang J, Wang X, Yuan J, Li X, Feng L, Park JI, Chen J. PTPN14 is required for the density-dependent control of YAP1. Genes Dev 26(17):1959-71, 2012. e-Pub 2012. PMID: 22948661.
      39. Hong JY, Park JI, Lee M, Muñoz WA, Miller RK, Ji H, Gu D, Ezan J, Sokol SY, McCrea PD. Down's-syndrome-related kinase Dyrk1A modulates the p120-catenin-Kaiso trajectory of the Wnt signaling pathway. J Cell Sci 125(Pt 3):561-9, 2012. e-Pub 2012. PMID: 22389395.
      40. Hong JY, Park JI, Cho K, Gu D, Ji H, Artandi SE, McCrea PD. Shared molecular mechanisms regulate multiple catenin proteins: canonical Wnt signals and components modulate p120-catenin isoform-1 and additional p120 subfamily members. J Cell Sci 123(Pt 24):4351-4365, 2010. e-Pub 2010. PMID: 21098636.
      41. Park JI, Venteicher AS, Hong JY, Choi J, Jun S, Shkreli M, Chang W, Meng Z, Cheung P, Ji H, McLaughlin M, Veenstra TD, Nusse R, McCrea PD, Artandi SE. Telomerase modulates Wnt signaling by association with target gene chromatin. Nature 460(7251):66-72, 2009. e-Pub 2009. PMID: 19571879.
      42. Lyons JP, Miller RK, Zhou X, Weidinger G, Deroo T, Denayer T, Park JI, Ji H, Hong JY, Li A, Moon RT, Jones EA, Vleminckx K, Vize PD, McCrea PD. Requirement of Wnt/beta-catenin signaling in pronephric kidney development. Mech Dev 126(3-4):142-59, 2009. e-Pub 2009. PMID: 19100832.
      43. Park JI, Ji H, Jun S, Gu D, Hikasa H, Li L, Sokol SY, McCrea PD. Frodo links Dishevelled to the p120-catenin/Kaiso pathway: distinct catenin subfamilies promote Wnt signals. Developmental Cell 11(5):683-95, 2006. e-Pub 2006. PMID: 17084360.
      44. Park JI, Kim SW, Lyons JP, Ji H, Nguyen TT, Cho K, Barton MC, Deroo T, Vleminckx K, Moon RT, McCrea PD. Kaiso/p120-catenin and TCF/beta-catenin complexes coordinately regulate canonical Wnt gene targets. Developmental Cell 8(6):843-54, 2005. e-Pub 2005. PMID: 15935774.
      45. Kim SW, Park JI, Spring CM, Sater AK, Ji H, Otchere AA, Daniel JM, McCrea PD. Non-canonical Wnt signals are modulated by the Kaiso transcriptional repressor and p120-catenin. Nature Cell Biology 6(12):1212-20, 2004. e-Pub 2004. PMID: 15543138.
      46. Fang X, Ji H, Kim SW, Park JI, Vaught TG, Anastasiadis PZ, Ciesiolka M, McCrea PD. Vertebrate development requires ARVCF and p120 catenins and their interplay with RhoA and Rac. J Cell Biol 165(1):87-98, 2004. e-Pub 2004. PMID: 15067024.
      47. Park JI, Lee MG, Cho K, Park BJ, Chae KS, Byun DS, Ryu BK, Park YK, Chi SG. Transforming growth factor-beta1 activates interleukin-6 expression in prostate cancer cells through the synergistic collaboration of the Smad2, p38-NF-kappaB, JNK, and Ras signaling pathways. Oncogene 22(28):4314-32, 2003. e-Pub 2003. PMID: 12853969.
      48. Byun DS, Cho K, Ryu BK, Lee MG, Park JI, Chae KS, Kim HJ, Chi SG. Frequent monoallelic deletion of PTEN and its reciprocal association with PIK3CA amplification in gastric carcinoma. Int J Cancer 104(3):318-27, 2003. e-Pub 2003. PMID: 12569555.
      49. Park BJ, Park JI, Byun DS, Park JH, Chi SG. Mitogenic conversion of transforming growth factor-beta1 effect by oncogenic Ha-Ras-induced activation of the mitogen-activated protein kinase signaling pathway in human prostate cancer. Cancer Res 60(11):3031-8, 2000. e-Pub 2000. PMID: 10850453.
      50. Kang MJ, Park BJ, Byun DS, Park JI, Kim HJ, Park JH, Chi SG. Loss of imprinting and elevated expression of wild-type p73 in human gastric adenocarcinoma. Clin Cancer Res 6(5):1767-71, 2000. e-Pub 2000. PMID: 10815895.
      51. Jung Y, Kim M, Suh HN, Lee SH, Jun S, Zhang J, Cervantes C, Johnson RL, Park AJ. Yap/Taz-activated Tert+ acinar cells are indispensable for pancreatic regeneration. Nature Communications.

      Invited Articles

      1. Zou G, Park JI. WNT Signaling in Liver Regeneration, Disease, and Cancer. Clin Mol Hepatol 29(1):33-50, 2023. e-Pub 2023. PMID: 35785913.
      2. Kim MJ, Huang Y, Park JI. Targeting Wnt Signaling for Gastrointestinal Cancer Therapy: Present and Evolving Views. Cancers (Basel) 12(12), 2020. e-Pub 2020. PMID: 33291655.
      3. Jung YS, Park JI. Wnt signaling in cancer: therapeutic targeting of Wnt signaling beyond β-catenin and the destruction complex. Exp Mol Med 52(2):183-191, 2020. e-Pub 2020. PMID: 32037398.
      4. McCrea PD, Park JI. Developmental functions of the P120-catenin sub-family. Biochim Biophys Acta 1773(1):17-33, 2007. e-Pub 2007. PMID: 16942809.

      Editorials

      1. Jung YS, Kim MJ, Park JI. LncGata6-controlled stemness in regeneration and cancer. Noncoding RNA Investig 3, 2019. PMID: 30775691.

      Abstracts

      1. Park JI, Venteicher AS, Hong JY, Jun S, Meng Z, Chang W, JI Ht JI, Veenstra, TD, Nusse R, McCrea PD Artandi SE. Telomerase is a ß-catenin cofactor in the Wnt signaling pathway. American Association for Cancer Research, San Francisco, 2007. e-Pub 2007.
      2. Lyons JP, Zhou X, Weidinger G, Denayer T, Park JI, Hong J, Deroo T, Jones EA, Moon RT, Vleminckx K, Vise PD McCrea PD. Wnt/ß-catenin signaling is required for pronephric kidney tubule development. Society for Molecular Imaging, 5th Annual Meeting, Hawaii, 2006. e-Pub 2006.
      3. Park J, Ji H, Jun S, Li L, Hikasa H, Sokol SY, McCrea PD. Frodo links dishevelled to the p120-catenin/Kaiso pathway: Members of distinct catenin sub-families promote Wnt signals in vertebrate development. Society for Developmental Biology, 65th Annual Meeting, Ann Arbor, MI, 2006. e-Pub 2006.
      4. Daniel JM, Park J, Donaldson NS, Ji H, McCrea PD. The POZ-ZFa transcription factor xZNF131: Roles in xenopus neurogenesis and p120ctn/Kaiso signaling?. Society for Developmental Biology, 65th Annual Meeting, AnnArbor, MI, 2006. e-Pub 2006.
      5. Park JI, Kim SW, Lyons, JP, Ji H, Nyguyen TT, Cho K, Barton MC, DeRoot T, Vleminckx K, Moon RT, McCrea PD. Kaiso/p120-catenin and TCF/ß-catenin complexes coordinately regulate canonical Wnt gene targets important in development and cancer progression. International Society for Developmental Biology congress, Sydney, Australia, 2005. e-Pub 2005.
      6. Park JI, Lyons JP, Ji H, Nguyen TT, Cho K, Barton MC, DeRoo T, Vleminckx K, Moon, RT, McCrea PD. Convergence of p120-catenin/Kaiso and ß-catenin/TCF gene regulation. Wnt signalling in Development, Disease and Cell Biology, Aberdeen, Scotland, 2005. e-Pub 2005.
      7. Park, JI, Lyons, JP, Ji H, Nguyen TT, Barton MC, Vleminckx K McCrea PD. Kaiso/p120-catenin and TCF/ß complexes coordinately regulate canonical Wnt gene targets. Society for Developmental Biology, 64th Annual Meeting, San Francisco, CA, 2005. e-Pub 2005.
      8. Park JI. Modeling cell plasticity and immune evasion using genetically engineered organoids. Annual Meeting of the Organoids Society 2024.
      9. Park JI. Tumorigenesis by deregulation of CRAD-controlled cytoskeleton dynamics. AACR 2018.
      10. Park JI. Minimum essential organoids culture media (MEOM) for murine esophageal organoids. DDW 2019.
      11. Park JI. A critical role of Wnt5a-Axin2 axis in small-cell lung cancer development. AACR 2020.
      12. Park JI. Overcoming mTOR inhibitor resistance by targeting the lysosomal deregulation. AACR SABCR 2021.
      13. Park JI. Modeling and dissecting poorly differentiated gastric cancer initiation. TMC Digestive Diseases Center 2022.
      14. Park JI. PCLAF/PAF-activated DREAM complex transcriptome is indispensable for alveolar cell lineage plasticity during lung regeneration. ISSCR 2022.
      15. Park JI. Modeling of CRACD/CRAD-Associated Gastric Cancer. DDW 2022.
      16. Park JI. Modeling and Dissecting of Esophageal Squamous Cell Carcinoma Initiation. AACR 2022.
      17. Park JI. CRACD/CRAD, an accelerator for gastric cancer development. AACR 2022.
      18. Park JI. Dissecting genetic interactions initiating esophageal squamous cell cancer and remodeling immune landscape. TMC Digenstive Diseases Center 2022.
      19. Park JI. CRACD/KIAA1211 loss drives cell plasticity and immune evasion of small cell lung cancer. AACR 2023.
      20. Park JI. Dysregulated Secretory Cell Plasticity by Aberrant CRACD-Actin-Regulon Is a Therapeutic Vulnerability of Mucinous Colon Cancer. IMKASID 2024.
      21. Park JI. Plasticity of Preneoplastic Cell Drives Esophageal Squamous Cell Cancer Initiation. AACR 2024.
      22. Park JI. Neuroendocrinal plasticity by CRACD-EZH2 accelerates progression and immune evasion of small cell lung cancer. NIH NCI Small Cell Lung Cancer Workshop 2024.
      23. Park JI. Dysregulated secretory cell Plasticity by aberrant CRACD-actin-regulon is a therapeutic vulnerability of mucinous colon cancer. KCA 2024.
      24. Park JI. Neuroendocrinal plasticity by CRACD-EZH2 accelerates progression and immune evasion of small cell lung cancer. KCA 2024.

      Book Chapters

      1. Huang Y, Zhang S, Park JI. Nuclear Actin Dynamics in Gene Expression, DNA Repair, and Cancer. In: Results Probl Cell Differ. Nature Springer, 625-663, 2022.
      Read More
      Less

      Patient Reviews


      CV information above last modified July 22, 2026

      Request an Appointment

      Whether you are ready to make an appointment now or have questions for our expert team, we are standing by to help.
      Learn more

      Related Links

      • Park Laboratory

      • Experimental Radiation Oncology department

      • Radiation Oncology division

      Clinical Trials

      Our patients have access to clinical trials offering promising new treatments that cannot be found anywhere else.
      Learn more

      Help #EndCancer

      Give Now

      Your gift will help make a tremendous difference.
      Donate

      Donate Blood

      Our patients depend on blood and platelet donations.

      Make an appointment

      Shop UT MD Anderson

      Show your support for our mission through branded merchandise.

      View products
      Subscribe to our Cancerwise newsletter
      UT MD Anderson logoUT MD Anderson logo
      • Explore
      • Patients & Family
      • Prevention & Screening
      • Donors & Volunteers
      • For Physicians
      • Research
      • Education & Training
      • Clinical Trials
      • Languages
      • About
      • About UT MD Anderson
      • Careers
      • Blog
      • Newsroom
      • Editorial Standards
      • For Employees
      • Merchandise
      • Title IX Reporting (Sexual Misconduct)
      • Price Transparency
      • Finding Your Way
      • Our Doctors
      • Locations
      • Directions
      • Sitemap
      • DIGITAL ACCESSIBILITY
      • Accessibility Policy MD Anderson works with Level Access to ensure our website is accessible and functional for all users. Free assistive technology is provided for people with physical disabilities. To learn more or to download the assistive technology tool, visit https://www.levelaccess.com/MDAnderson
      • GET IN TOUCH
      • Call
        1-877-632-6789
      • Ask a question
      • Stay Connected
      • Cancerwise Podcast
      • More
      • Website Privacy Policy
      • Legal Statement & Policies
      • Reports to the State
      • Emergency Alert Information
      • State of Texas Links
      • Our Cancer Network
      • Vendors & Suppliers
      UT MD Anderson logo
      The mission of The University of Texas MD Anderson Cancer Center is to eliminate cancer in Texas, the nation, and the world through outstanding programs that integrate patient care, research and prevention, and through education for undergraduate and graduate students, trainees, professionals, employees and the public.

      © 2026 The University of Texas MD Anderson Cancer Center. All rights reserved.

      Top